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Stability studies correspond to a set of tests designed to assess changes in the quality of a given drug over time and under the 
influence of a number of factors. Among these factors, pH plays an important role, due to the catalytic effect that hydronium and 
hydroxide ions can play in several reactions. In the present study, the degradation kinetics of nitazoxanide was evaluated over a 
wide pH range, and the main degradation product generated was identified by LC-MS/MS. Nitazoxanide showed first-order 
degradation kinetics in the pH range of 0.01 to 10.0 showing greater stability between pH 1.0 and 4.0. The degradation rate constant 
calculated for these pH was 0.0885 x 10-2 min-1 and 0.0689 x 10-2 min-1, respectively. The highest degradation rate constant value 
was observed at pH 10.0 (0.7418 x 10-2 min-1) followed by pH 0.01 (0.5882 x 10-2 min-1). A major degradation product (DP-1) was 
observed in all conditions tested. Through LC-MS/MS analysis, DP-1 was identified as a product of nitazoxanide deacetylation. 
The effect of pH on the stability of nitazoxanide and the kinetic data obtained contribute to a better understanding of the intrinsic 
stability characteristics of nitazoxanide. 
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Introduction  
 
Nitazoxanide (NTZ) is a thiazolide antiparasitic drug agent, 
that was first described in 1984 as a human cestocidal drug 
which was effective in a single dose against Taenia saginata 
and Hymenolepis nana [1, 2]. NTZ is active against a broad 
range of organisms including protozoa, helminths, viruses 
and bacteria. In vivo, NTZ is rapidly converted to its also 
active metabolite tizoxanide through a deacetylation [1,2]. 
The activity of NTZ and main active metabolite is believed to 
be due to its interference with the reaction of electron 
transfers dependent on the pyruvate:ferredoxin 
oxidoreductase enzyme, essential for the anaerobic energy 
metabolism [1-4]. 
Chemically, NTZ (Figure 1) can be denominated 2-
acetolyloxy-N-(5-nitro-2-thiazolyl) benzamide with 
molecular formula C12H9N3O5S. It is characterized as a bright 
yellow crystalline powder, practically insoluble in water and 
poorly soluble in ethanol. NTZ is commercially available as 
coated tablets (500 mg) and oral suspension powder (20 
mg/mL) [5]. 
 
 
Figure 1. Chemical structure of  NTZ. 
 
The chemical stability of NTZ is reported in some studies. 
Malesuik et al. (2012) studied the behavior of the drug in  
 
 
solution and solid state under stress conditions, where the 
major product formed was identified as the result of NTZ 
deacetylation [6]. Photodegradation of NTZ was studied by 
Malesuik et al (2009) by exposing the drug to UV-C light at 
254 nm. Under this condition, the drug showed zero-order 
degradation kinetics, and the suggested reactions for drug 
degradation is through cleavage of the amide group, forming 
aminonitrothiazol and acetilsalisilic acid, and reductive nitro 
compounds [7]. Ali et al (2012) also reported NTZ 
degradation when diluted in 1.0 M HCl and 0.1 M NaOH [8]. 
Considering the influence of pH on drug degradation and the 
already reported instability of NTZ in HCL and NaOH 
aqueous solutions, the present work aimed to evaluate the 
degradation kinetics of NTZ over a wide pH range, 
identifying the degradation products generated through LC-
MS/MS. 
 
Experimental 
Chemicals and apparatus  
Nitazoxanide was donated by Althaia S/A Pharmaceutical 
Industry (Atibaia, São Paulo, Brasil) with declared purity of 
99.50%. Acetonitrile was obtained from Merck (Darmstadt, 
Germany). Orthophosphoric acid and hydrochloric acid were 
obtained from Merck (Darmstadt, Germany). Sodium 
hydroxide and potassium phosphate monobasic from Synth 
(São Paulo, Brazil). Purified water was obtained using a 
Milli‐Q Plus® system (Millipore, Bedford, USA).  
Quantitative analyzes were performed by high performance 
liquid chromatography (HPLC), using a method developed 
and validated by Malesuik et al. (2008), according to the 
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following conditions: Column XBridgeTM C-18 (250 x 4.6 
mm, i.d., 5 m particle size) (Waters, Wexford, Ireland);  
mobile phase o-phosphoric acid 0.1% (v/v) acetonitrile 
(45:55, v/v); pH of aqueous phase adjusted to 3.0 to obtain a 
better resolution between NTZ and degradation product; UV–
vis detector set to 240; injection volume of 20 μL [9]. 
The analyzes were performed on a Prominence® Liquid 
Chromatograph Shimadzu, equipped with a degasser DGU‐
20A5, an LC‐20AC pump, a SIL‐20AC autosampler, an SPD‐
M20A PDA detector and a CTO‐20 AC column oven 
(Shimadzu, Kyoto, Japan). LC Solution V. 1.24 SP1 system 
software was used to control the equipment and to calculate 
data and responses from the LC system. 
 
Sample preparation 
 
A stock solution of NTZ 400 µg/mL was firstly prepared. For 
it, 40 mg of NTZ was weighted and transferred to 100 mL 
volumetric flask, 70 mL of acetonitrile was added and the 
sample was taken to ultrasonic bath for 10 minutes, followed 
by adding the same solvent to make up to volume. Starting 
from the stock solution, samples were diluted to 100 g/mL 
using 1 M HCl (pH 0.01) and 0.1 M HCl (pH 1.0) and in 25 
mM phosphate buffer at pH 4.0; 6.0; 8.0; 10.0; 12.0. All 
samples were stored at 40 °C, and aliquots were withdrawn in 
time intervals, until a decay of approximately 50% of its 
initial content. The samples were diluted 1:1 in mobile phase 
and immediately analyzed by HPLC. 
 
Kinetic calculations 
 
The degraded samples were quantitatively analyzed by HPLC 
and the degradation rate kinetics were determined by plotting 
concentration of drug remaining vs time (zero-order process); 
ln concentration of drug remaining vs time (first‐order 
process) and the inverse of the concentration vs time (second‐
order process). The regression coefficients (r) were obtained, 
and the best fit observed indicates the reaction order. 
According to the reaction order, the degradation rate constant 
(k), half‐life time (T1/2) and time where 90% of original 
concentration of the drug was left unchanged (T90%) were 
calculated. 
These kinetic models can be represented by the following 
equations [10, 11]: 
 
Zero-order reaction: 
 
 
 
First-order reaction 
 
 
 
Second‐order reaction 
 
Where “C0” represents the initial concentration, “C” the  
 
Where 𝐶 is the final concentration, 𝐶0  is the initial 
concentration, 𝑘 is the reaction rate constant and 𝑡 represents 
the reaction time. 
 
 
LC-MS/MS analyzes 
 
The LC-MS/MS analyses were performed on Waters 
Acquity® Ultra Performance Liquid Chromatographic system 
(Waters Corp., Milford, USA) coupled to mass spectrometer 
Micromass Q-Tof micro (Waters Corp., Milford, USA), 
equipped with an ESI interface operating in positive ion mode 
using a capillary voltage of 3.0 kV. The other optimum values 
of the ESI‐Q‐TOF parameters were source temperature 100 
°C; Desolvation temperature 300 °C; Desolvation gas (N2) 
flow 600 L/Hour. The detection was made considering a mass 
range of 100 – 800 m/z. The mobile phase consisted of water 
containing 0.1% formic acid and acetonitrile with 0,1 % 
formic acid (45:55 v/v) at a flow rate of 0.2 mL/min. A 
Zorbax Eclipse Plus C-18 column (2.5 x 50 mm, i.d., 1.8 m 
particle size) (Agilent Technologies, CA, USA) was used. 
 
Results and discussion 
 
Kinetic degradation     
 
Kinetics reactions for NTZ were studied in order to recognize 
the drug behavior along decomposition time, and to 
determine the reaction order and related parameters. The pH-
rate degradation profile was determined in the pH range 0.01 
- 10.0 at 40 °C. According to Yoshioka and Stella (2002) the 
effect of pH on degradation rate can be explained by the 
catalytic effects that hydronium or hydroxide ions can have 
on various chemical reactions [12]. The reactions dependent 
on the activity of hydronium and hydroxide ions, performed 
at constant pH, generally follow pseudo-first order kinetics. 
In a reaction in which hydronium ion, hydroxide ion, and 
water catalysis are observed can be described by: 
 
𝑘𝑜𝑏𝑠 = 𝑘𝐻+𝑎𝐻+ +  𝐻2𝑂 +  𝑘𝑂𝐻−𝑎𝑂𝐻−    
 
Where kobs is the sum of the degradation constants specific for 
each degradation pathway (acid or alkaline), and aH+ and aOH-
 
correspond to the activity of the hydronium and hydroxide 
ions, respectively. 
For the determination of the reaction order, the degradation 
kinetic was calculated for all conditions through the decrease 
in drug concentration by time. The concentration, ln, and 
reciprocal concentration plots of remaining drug versus time 
were evaluated, and according to the correlation coefficient 
obtained, it can be concluded that the degradation of NTZ 
under the studied conditions follows first-order reaction 
kinetics. The obtained correlation coefficients presented in 
Table 1.The influence of pH on the reaction rate constant is 
shown in Table 2 and Figure 2. In the study we can observe a 
greater stability of the drug in solutions with slightly acidic 
pH, being more stable between pH 1.0 and 4.0. The 
conditions leading to the highest drug degradation were pH 
0.01 and 10.0 which showed a constant reaction rate of 
0.5882 x 10-2 and 0.7418 x 10-2 min-1, respectively. The 
stability of NTZ at pH 12 at 40 °C was also evaluated. In this 
condition, total drug degradation occurred after 20 minutes of 
storage. 
 
 
1/𝐶 = 1/𝐶0 − 𝑘𝑡      𝑡1
2⁄
= 1/𝑘𝐶0    𝑡90% = 1/9𝑘𝐶0   
𝐶 = 𝐶0 − 𝑘𝑡      𝑡1
2⁄
= 𝐶0 − 2𝑘    𝑡90% = 0.1𝐶0/𝑘         
𝑙𝑛𝐶 = 𝑙𝑛𝐶0 − 𝑘𝑡      𝑡1
2⁄
= ln 2 /𝑘    𝑡90% = 0.106/𝑘  
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Table 1. Correlation coefficient values for reaction order 
obtained in determining the stability of NTZ at different pH 
values at 40 °C. 
 Correlation coefficient (r) 
pH  Zero-order  First-order Second-order 
0.01 0.9856 0.9980 0.9714 
1.0 0.9980 0.9984 0.9973 
4.0 0.9983 0.9986 0.9982 
6.0 0.9988 0.9998 0.9936 
8.0 0.9955 0.9986 0.9903 
10 0.9831 0.9962 0.9508 
 
Table 2. Degradation rate constant (k), t90% and half-life (t1/2) 
for NTZ at different pH values and a temperature of 40 °C 
pH 
reaction rate 
constant (k) (min-1) 
t90% 
(min) 
t1/2  
(min) 
0.01 0.5882 x 10-2 18.02 117.84 
1.0 0.0885 x 10-2 119.77 783.22 
4.0 0.0689 x 10-2 153.85 1006.02 
6.0 0.2634 x 10-2 40.24 263.15 
8.0 0.3401 x 10-2 31.17 203.81 
10 0.7418 x 10-2 14.29 93.44 
 
 
Figure 2. pH-rate profile for the degradation of NTZ at 40 °C. 
 
Degradation products 
 
Through chromatographic analyzes it was possible to observe 
the formation of a major degradation product, named DP-1. 
This degradation product was formed in the pH range of 0.01 
- 10.0, and started to be detected in all these conditions, after 
20 minutes of storage. It was also possible to visualize a 
second degradation product named DP-2, which started to be 
detected after 40 minutes in a pH 10.0 solution.  
Figure 3 shows representative chromatograms of the analyzes 
carried out for the samples solubilized at pH 6, where it is 
possible to observe the increase in the concentration of DP-1 
over time. This same behavior was observed in the pH range 
of 0.01 to 8.0. Figure 4 shows the representative 
chromatograms of the analyzes performed for the samples 
solubilized at pH 10.0, where it is possible to observe the 
formation of the second degradation product after 40 minutes 
of storage, indicated as DP-2. For samples solubilized at pH 
12.0, an extensive degradation of the drug was observed, and 
it is not possible to calculate its kinetic parameters. Also in 
this condition, the formation of the degradation product DP-
1 was not observed, only DP-2 was generated. 
 
Figure 3. Chromatograms showing decomposition of NTZ in 
pH 6 solution at 40 °C, at different times of degradation. 
 
 
 
Figure 4. Chromatograms showing decomposition of NTZ in 
pH 10 solution at 40 °C, at different times of degradation. 
 
In the pH range from 1.0 to 8.0, the formation of the 
degradation product DP-1 occurred directly proportional to 
the decay of the NTZ concentration, at all times analyzed, 
indicating only the formation of this degradation product. The 
same profile was not observed at pH of 0.01 and 10.0, due to 
the formation of a second degradation product (DP-2), 
visualized in the chromatographic analysis, and also the 
possible formation of other undetected products.  
The Relative Mass Balance Deficit (RMBD) was calculated 
to demonstrate the correlation between the degradative losses 
of NTZ with the increase measured in the degradation 
products. The concentration of degradation products was 
calculated through the relative peak area, assuming both to 
have the same response factor in HPLC analysis. 
The RMBD was calculated according to the equation [13,14]:  
 
𝑅𝑀𝐵𝐷 = 100% × 
(𝑀𝑛𝑡𝑧,0 − 𝑀𝑛𝑡𝑧,𝑋) − (𝑀𝑑𝑝,𝑋 − 𝑀𝑑𝑝,0) 
𝑀𝑛𝑡𝑧,0 − 𝑀𝑛𝑡𝑧,𝑋
   
 
Where, 𝑀𝑛𝑡𝑧,0 represents the concentration of NTZ in the 
initial time, 𝑀𝑛𝑡𝑧,𝑋 the concentration of NTZ after a 
determined time of degradation. 𝑀𝑑𝑝,0 represents the 
concentration of the degradation products at the initial time 
and 𝑀𝑑𝑝,𝑋 the concentration of the degradation products after 
a determined time of degradation. For all pH tested, RMBD 
was calculated when the drug showed a degradation of 
approximately 10 % of its initial content. The calculated 
RMBD values are shown in Table 3. 
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Table 3. Values of the relative deficit of the mass balance 
obtained in the evaluation of the stability of NTZ at different 
pHs at 40 °C. considering a decay of approximately 10 % of 
its initial content. 
pH NTZ (%) DPs (%) RMBD 
0.01 84.02 15.49 3.05 % 
1.0 90.43 9.56 0.10% 
4.0 89.55 10.33 1.10 % 
6.0 91.97 8.11 0.02 % 
8.0 89.94 9.80 2.49 % 
10.0 84.07 15.54 2.42 % 
 
In the case of a perfect mass balance, the RMBD will have a 
zero value. The same will be positive when the measured 
increase in degradation products is less than the loss of parent, 
and negative when the measured increase in degradation 
products exceeds the loss of parent [19,20]. In our study, 
considering a degradation of approximately 10% of its initial 
content, the low values of RMBD presented demonstrate that 
the degradation products are generated proportionally to the 
decay of the NTZ concentration. When calculated 
considering the final experiment time (degradation of 
approximately 50%), the RMBD presented higher values, 
possibly due to the formation of secondary degradation 
products. 
 
Identification of degradation products   
 
For the identification of the formed degradation products, 
mainly the major product, named as DP-1, the samples were 
analyzed by LC-MS/MS. A chromatogram representing the 
analysis is shown in Figure 5. In figure 5(A) a total ion 
chromatogram is shown, where two peaks are observed, in the 
retention times of 2.30 and 2.98 min. The peak at 2.30 refers 
to NTZ ([M + H]+ 308), and the peak at 2.98 refers to 
degradation product DP-1 ([M + H]+ 266). Figures 5(B) and 
5(C) show the extracted ion chromatograms from masses 308 
and 266, respectively. 
To aid identification, additional fragmentation experiments 
(MS/MS) of these ions were performed fragmentation by a 
collision-induced dissociation (CID) process was performed 
with collision energy of 15 eV, and the spectra are shown in 
Figure 6. 
The chemical structures, as well as the structure of the most 
probable of fragments formed are shown in Figures 7 and 8. 
Figure 7 shows the characteristic fragmentation of the NTZ 
molecule, with deacetylation giving rise to the m/z 266 
fragment followed by the cleavage of the amide, resulting in 
m/z 121 fragment. The m/z 163 fragment is generated by 
cleavage of the amide, without deacetylation. 
 
Figure 5. Representative chromatogram of the LC-MS/MS 
analysis of the degraded NTZ sample at pH 10.0 at 40 °C. 
5(A) total ion chromatography. 5(B) and 5(C) extracted ion 
chromatogram m/z 308 and m/z 266, respectively. 
 
 
Figure 6. MS/MS spectra of [M+H]+ ions from NTZ (A); and 
degradation product (DP-1) (B). CID at 15 eV. 
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Figure 7. Chemical structure and proposed fragmentation 
route for the protonated NTZ molecule, identified from the 
MS/MS analysis. 
 
The degradation product DP-1 shown in figure 8, has the 
same structure as tizoxanide, the main active metabolite of 
NTZ. In vivo, this reaction occurs rapidly through the action 
of plasma stearases [2,3]. In work carried out by Ali and 
collaborators (2012), the NTZ was subjected to different 
conditions of forced degradation, and this degradation 
product is also reported. In this work, it was formed after 
degradation in 0.1 M NaOH at room temperature, and after 
degradation in 1.0 M HCl under reflux [8]. In our study, this 
reaction occurred more quickly in an alkaline medium, due 
to the nucleophilic attack on carbonyl. 
 
 
Figure 8. Chemical structure and proposed fragmentation 
route for the protonated DP-1 molecule, identified from the 
MS/MS analysis. 
 
Conclusion  
 
The determination of kinetic parameters of NTZ showed 
greater stability in acidic pH, between 1.0 and 4.0, and more 
unstable at pH close to neutrality and slightly alkaline. The 
calculated RMBD showed low values indicating the detection 
of all formed degradation products, and the analysis by LC-
MS/MS allowed the identification of the main formed 
degradation product. The results obtained contribute to a 
better understanding about intrinsic stability characteristics of 
nitazoxanide. 
 
Reference 
 
1 White Jr AC. Nitazoxanide: a new board spectrum 
antiparasitic agent. Expert Rev Anti-infect Ther. 2014; 2(1): 
43 – 50. 
 
2 Gilles HM, Hoffman PS. Treatment of intestinal parasitic 
infections: a review of nitazoxanide. Trends parasitol. 2002; 
18: 95 – 97. 
 
3 Fox LM, Saravolatz LD. Nitazoxanide: A New Thiazolide 
Antiparasitic Agent. Clin Infect Dis. 2005; 40: 1173 – 80. 
 
4 Anderson VR, Curran MP. Nitazoxanide: a review of its use 
in the treatment of gastrointestinal infections. Drugs. 2007; 
67(13): 1947 – 67. 
 
5 Farmoquímica S/A. Anitta® 500 mg. Rio de Janeiro. 2016. 
 
6 Malesuik MD, Gonçalves HM, Garcia CV, Trein MR, 
Nardi NB, Schapoval EES, Steppe M. Identification, 
characterization and cytotoxicity in vitro assay of 
nitazoxanide major degradation product. Talanta. 2012; 93: 
206 – 211. 
 
7 Malesuik MD, Gonçalves HML, Paim CS, Schapoval EES, 
Steppe M. LC: Analysis of Photodegradation Kinetics of 
Nitazoxanide in Pharmaceutical Formulations. J Chromatogr 
Sci. 2009; 47: 745 – 748. 
 
8 Ali NW, Abbas SS, Zaazaa HE, Abdelrahman MM, 
Abdelkawy M. Validated stability indicating methods for 
determination of nitazoxanide in presence of its degradation 
products. J Pharm Anal. 2012; 2: 105 – 116. 
 
9 Malesuik DM, Cardoso SG, Steppe M. Development of a 
Validated Stability Indicating LC Method for Nitazoxanide in 
Pharmaceutical Formulations. Chromatographia. 2008; 67: 
131 – 136. 
 
10 Nuldeman NS. Estabilidad de medicamentos. 1ª edição, 
Buenos Aires, El Ateneo. 1975. 
 
11 Sinko PJ. Martin- físico-farmácia e ciências 
farmacêuticas. 5ª ed. Artmed, 2008. 
 
12 Yoshioka S, Stella VS. Chemical Stability of Drug 
Substances. In: Stability Drugs and Dosage Forms. New 
York: Kluwer Academic/Plenum; 2000, p. 3 – 135. 
 
13 Baertschi SW, Pack BW, Hyzer CSH, Nussbaum MA. 
Assessing mass balance in pharmaceutical drug products: 
New insights into an old topic. Trends Anal Chem. 2013; 39: 
226 – 236. 
 
Drug Anal Res, v. 4, n. 1, 12-17, 2020 
 
17 
14 Nussbaum MA, Jansen PJ, Baertschi SW. Role of ‘‘Mass 
Balance’’ in Pharmaceutical Stress Testing. Pharmaceutical 
Stress Testing Predicting Drug Degradation. 2° ed. Informa 
Healthcare. 2011.  
  
 
